We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+18.88%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$219M
(-12%)
Cap. Flow
-$413M
Cap. Flow
% of AUM
-25.11%
Top 10 Holdings %
Top 10 Hldgs %
53.34%
Holding
74
New
16
Increased
18
Reduced
15
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$65.6M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$48.9M |
| 3 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$32.5M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$31.9M |
| 5 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$30.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$92.3M |
| 2 |
Zimmer Biomet
ZBH
|
+$77.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$62.1M |
| 4 |
AGN
Allergan plc
AGN
|
+$54.4M |
| 5 |
AbbVie
ABBV
|
+$47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.57% |
| 2 | Consumer Staples | 9.02% |
| 3 | Financials | 4.8% |
| 4 | Materials | 0.45% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $155M | 9.39% |
10,000,000
-1,000,000
| -9% | -$14.7M |
|
|
2
McKesson
MCK
$101B
| $96.8M | 5.88% |
600,000
+426,782
| +246% | +$65.6M |
|
|
CBST
3
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $96.4M | 5.86% |
1,400,000
+475,000
| +51% | +$30.7M |
|
|
ARTC
4
DELISTED
ARTHROCARE CORP
ARTC
| $95.6M | 5.81% |
2,375,000
+75,000
| +3% | +$2.78M |
|
|
WMGI
5
DELISTED
Wright Medical Group Inc
WMGI
| $93.7M | 5.69% |
3,050,000
+50,000
| +2% | +$1.42M |
|
|
AGN
6
DELISTED
Allergan Inc
AGN
| $91.6M | 5.57% |
825,000
+280,000
| +51% | +$26.7M |
|
7
eHealth
EHTH
$43.8M
| $79M | 4.8% |
1,700,000
-552,119
| -25% | -$23M |
|
|
AEGR
8
DELISTED
Aegerion Pharmaceuticals
AEGR
| $60.3M | 3.66% |
850,000
+425,000
| +100% | +$32.5M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $59.8M | 3.63% |
450,000
+50,000
| +13% | +$6M |
|
|
MJN
10
DELISTED
Mead Johnson Nutrition Company
MJN
| $50.3M | 3.05% |
+600,000
| New | +$48.9M |
|
|
WBMD
11
DELISTED
WebMD Health Corp.
WBMD
| $45.4M | 2.76% |
1,150,000
+700,000
| +156% | +$25.3M |
|
12
Molina Healthcare
MOH
$10.2B
| $44.3M | 2.69% |
1,275,000
+175,000
| +16% | +$5.9M |
|
13
CALL
Teva Pharmaceuticals
TEVA
$41.2B
| $40.1M | 2.43% |
+1,000,000
| New | +$39.4M |
|
|
DVAX
14
DELISTED
Dynavax Technologies
DVAX
| $39.2M | 2.38% |
2,000,000
+240,000
| +14% | +$3.51M |
|
15
CALL
Abbott
ABT
$183B
| $38.3M | 2.33% |
+1,000,000
| New | +$36.9M |
|
|
WWAV
16
DELISTED
The WhiteWave Foods Company
WWAV
| $37.9M | 2.3% |
1,650,000
-625,000
| -27% | -$13M |
|
|
SLXP
17
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $36M | 2.19% |
+400,000
| New | +$31.9M |
|
18
Agilent Technologies
A
$39.2B
| $35.7M | 2.17% |
873,750
-174,750
| -17% | -$6.64M |
|
|
BEAM
19
DELISTED
BEAM INC COM STK (DE)
BEAM
| $34M | 2.07% |
500,000
-225,000
| -31% | -$15.2M |
|
20
Viatris
VTRS
$20.7B
| $31.5M | 1.91% |
725,000
-475,000
| -40% | -$19.5M |
|
|
RLYP
21
DELISTED
RELYPSA INC COM
RLYP
| $27.5M | 1.67% |
+1,100,000
| New | +$22.6M |
|
22
Estee Lauder
EL
$30.7B
| $26.4M | 1.6% |
350,000
+50,000
| +17% | +$3.62M |
|
23
Innoviva
INVA
$1.57B
| $25.8M | 1.57% |
899,725
+31,025
| +4% | +$908K |
|
24
Tenet Healthcare
THC
$20.3B
| $25.3M | 1.54% |
600,000
-250,000
| -29% | -$10.9M |
|
|
NUVA
25
DELISTED
NuVasive, Inc.
NUVA
| $25.1M | 1.52% |
775,000
+350,000
| +82% | +$10.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2013 Portfolio in Review
As of Q4 2013, HealthCor Management held 74 positions worth $1.65B, down 12% from $1.87B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
HealthCor Management withdrew a net $413M in Q4 2013, closing 25 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $47M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, HealthCor Management opened a new position in Mead Johnson Nutrition Company worth $50.3M.
- HealthCor Management's largest Q4 2013 buy was Mead Johnson Nutrition Company: 600,000 shares worth $50.3M.
- HealthCor Management added most to McKesson in Q4 2013, an estimated $65.6M increase.
- HealthCor Management's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $92.3M.
- HealthCor Management fully exited AbbVie in Q4 2013, selling an estimated $47M.
- HealthCor Management's ten largest holdings make up 53% of its $1.65B portfolio in Q4 2013.
- HealthCor Management opened 16 new positions and closed 25 in Q4 2013.
- HealthCor Management's portfolio value fell 12% quarter-over-quarter to $1.65B.
Based on HealthCor Management's 13F filing for Q4 2013, filed 14 Feb 2014.